MilliporeSigma Commits $286 Million toward US Biosafety Testing
Drug safety analysis to be conducted at Rockland, MD facility
MilliporeSigma, a contract development and manufacturing organization (CDMO) and life science business of Merck, is investing more than $286 million in its biosafety testing capacity at the company’s site in Rockville, MD. The testing will be conducted at the CDMO’s 250,000 square-foot facility.
This financial commitment is expected to significantly increase the company’s ability to conduct biosafety testing and analytical development services, requirements that are fundamental to the drug development and commercialization process as it pertains to the safety of medicines.
“MilliporeSigma is harnessing its broad portfolio of modern technologies and enabling services to help ensure the safety of the world’s medicines. These significant investments in Rockville and other sites across our global network will help us meet growing demand for the robust testing studies that biologics manufacturers depend upon to comply with stringent regulatory guidelines,” says Belén Garijo, chair of the executive board and CEO of Merck KGaA, Darmstadt, Germany. “This is a prime example of our focus on sustainable growth in areas with strong underlying upwards dynamics.”
Read more about the CDMO’s investment here.
